Covered recipient · General Payments record
SAKIB S QURESHI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2019–2025
$18,052.18
- Reported across 560 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,300.00 | 2 |
| Food and Beverage | $1,633.95 | 81 |
| Travel and Lodging | $972.39 | 2 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| PFIZER INC. | $7,432.36 | 9 |
| ABBVIE INC. | $421.48 | 33 |
| TG THERAPEUTICS, INC. | $113.36 | 4 |
| EISAI INC. | $101.82 | 4 |
| Lilly USA, LLC | $64.72 | 3 |
| ARGENX US, INC. | $62.73 | 3 |
| Axsome Therapeutics, Inc. | $55.90 | 2 |
| Biogen, Inc. | $54.82 | 2 |
| Vanda Pharmaceuticals Inc. | $52.29 | 1 |
| Otsuka America Pharmaceutical, Inc. | $49.72 | 2 |
| UCB, Inc. | $45.39 | 1 |
| Ascendis Pharma Endocrinology Inc | $43.24 | 2 |
| ACADIA Pharmaceuticals Inc | $42.04 | 2 |
| GE HEALTHCARE | $40.90 | 1 |
| SK Life Science, Inc. | $32.96 | 1 |
| Abbott Laboratories | $32.80 | 2 |
| SpringWorks Therapeutics, Inc. | $30.70 | 1 |
| Medtronic, Inc. | $30.10 | 2 |
| Lundbeck LLC | $28.86 | 1 |
| Xeris Pharmaceuticals, Inc. | $24.14 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $21.91 | 1 |
| FORTE BIO-PHARMA LLC | $21.00 | 1 |
| MannKind Corporation | $20.30 | 1 |
| Averitas Pharma Inc. | $20.06 | 1 |
| Novo Nordisk AS | $17.37 | 1 |
| GlaxoSmithKline, LLC. | $15.75 | 1 |
| Amneal Pharmaceuticals LLC | $15.52 | 1 |
| Amgen Inc. | $14.10 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (85)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.